

Short report

Open Access

## High level expression of the anti-retroviral protein APOBEC3G is induced by influenza A virus but does not confer antiviral activity

Eva-K Pauli<sup>1</sup>, Mirco Schmolke<sup>1</sup>, Henning Hofmann<sup>2</sup>, Christina Ehrhardt<sup>1</sup>, Egbert Flory<sup>3</sup>, Carsten Münk<sup>2</sup> and Stephan Ludwig\*<sup>1</sup>

Address: <sup>1</sup>Institute of Molecular Virology (IMV), Centre of Molecular Biology of Inflammation (ZMBE), Westfaelische-Wilhelms-University Muenster, Münster, Germany, <sup>2</sup>Clinic for Gastroenterology, Hepatology and Infectiology, Heinrich-Heine-University, Duesseldorf, Germany and <sup>3</sup>Paul-Ehrlich-Institute (PEI), Langen, Germany

Email: Eva-K Pauli - [evapauli@uni-muenster.de](mailto:evapauli@uni-muenster.de); Mirco Schmolke - [mirco.schmolke@uni-muenster.de](mailto:mirco.schmolke@uni-muenster.de); Henning Hofmann - [Henning.Hofmann@med.uni-duesseldorf.de](mailto:Henning.Hofmann@med.uni-duesseldorf.de); Christina Ehrhardt - [ehrharc@uni-muenster.de](mailto:ehrharc@uni-muenster.de); Egbert Flory - [floeg@pei.de](mailto:floeg@pei.de); Carsten Münk - [Carsten.Muenk@med.uni-duesseldorf.de](mailto:Carsten.Muenk@med.uni-duesseldorf.de); Stephan Ludwig\* - [ludwigs@uni-muenster.de](mailto:ludwigs@uni-muenster.de)

\* Corresponding author

Published: 16 April 2009

Received: 31 October 2008

*Retrovirology* 2009, **6**:38 doi:10.1186/1742-4690-6-38

Accepted: 16 April 2009

This article is available from: <http://www.retrovirology.com/content/6/1/38>

© 2009 Pauli et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

### Abstract

Human APOBEC3G is an antiretroviral protein that was described to act via deamination of retroviral cDNA. However, it was suggested that APOBEC proteins might act with antiviral activity by yet other mechanisms and may also possess RNA deamination activity. As a consequence there is an ongoing debate whether APOBEC proteins might also act with antiviral activity on other RNA viruses. Influenza A viruses are single-stranded RNA viruses, capable of inducing a variety of antiviral gene products. In searching for novel antiviral genes against these pathogens, we detected a strong induction of APOBEC3G but not APOBEC3F gene transcription in infected cells. This upregulation appeared to be induced by the accumulation of viral RNA species within the infected cell and occurred in an NF- $\kappa$ B dependent, but MAP kinase independent manner. It further turned out that APOBEC expression is part of a general IFN $\beta$  response to infection. However, although strongly induced, APOBEC3G does not negatively affect influenza A virus propagation.

### Findings

In patients infected with HIV-1, the expression of human apolipoprotein (apo) B mRNA editing enzyme catalytic polypeptide 1-like protein 3G (APOBEC3G) was observed to be elevated [1], although this was not confirmed in cell culture experiments [2,3]. Members of the APOBEC3 family are known to act with anti-retroviral activity against HIV [4,5], but they also inhibit replication of hepatitis B virus (HBV) [6], and adeno-associated virus type 2 [7]. The anti-retroviral activity of human APOBEC3 proteins is probably conferred by cytidine deamination of the newly synthesized first viral cDNA strand. This mechanism is counteracted by the HIV-1 protein virion infectivity factor

(Vif) [8-12]. However, human APOBEC3 proteins may not only have anti-retroviral or anti-HBV activity. Two findings have triggered a broader interest in these proteins with regard to a potential antiviral action against RNA viruses. First, besides its DNA deamination activity, human APOBEC3 proteins were reported to also possess RNA deamination activity [13]. Second, DNA deamination activity may not be the only antiviral action of these proteins [13-16] suggesting that APOBEC3s might possess functions that render them effective against other viruses, which do not have any DNA-intermediates during replication such as influenza A virus.

In global gene expression profiling studies of influenza A virus-infected cells, we observed strongly elevated transcription of human APOBEC3G. This finding was verified by quantitative Real-time PCR (qRT-PCR) [17] with specific primers against APOBEC3G and APOBEC3F (Figure 1A) [18-20] in lung epithelial cells (A549) (Figure 1B) and in primary human endothelial cells (HUVEC) (Figure 1C) infected with the human influenza virus A/Puerto Rico/8/34 H1N1 (PR8). The upregulation of APOBEC3G was also confirmed on protein level as determined in Western blot analysis (Figure 1E). Protein expression steadily increased with time up to 16 hours post infection but dropped again at 24 hours p.i (Figure 1E) most likely due to host cell protein shut-off induced by the virus. Interestingly, such an upregulation of human APOBEC3G transcription was not reported for cells infected with HIV-1 [2,3], although higher expression levels of human APOBEC3G in HIV-1 infected patients is described in the literature [1]. Upregulation of APOBEC3G was also confirmed in cells infected with the human H5N1 influenza virus isolate A/Thailand/(KAN-1)/2004 (H5N1) (data not shown), suggesting that transcriptional induction of APOBEC3G is a general phenomenon in influenza A virus infected cells. Interestingly, the paralogue human APOBEC3F was not found to be upregulated in A549 cells and was only marginally induced in HUVEC (Figure 1B and 1C). This is noteworthy, since human APOBEC3F and human APOBEC3G share more than 90% promoter sequence similarity and appear to be transcriptionally co-regulated [4,5]. However, co-regulated induction of expression was not observed in our experiments. Instead we found that the mRNA copy number of APOBEC3F remains at a constant high level in uninfected and infected A549 cells, while the copy numbers of APOBEC3G are at a low level in uninfected cells and rise upon viral infection (Figure 1D), suggesting distinct transcriptional regulation despite high promoter sequence similarity.

Given the particular strong induction of human APOBEC3G in influenza A virus-infected cells, we addressed the question which virus-induced intracellular signalling pathways are required for human APOBEC3G mRNA transcription. Influenza virus infection induces a variety of signalling pathways such as the Raf/MEK/ERK kinase cascade, the p38 signalling pathway and the IKK/NF $\kappa$ B pathway [21,22]. PMA, an effective inducer of the classical Raf/MEK/ERK cascade, has been reported to induce human APOBEC3G gene expression in H9 cells via PKC [23]. However, in the cell types used in our study, PMA (100–200 ng/ml) was only a weak inducer of APOBEC3G expression, and inhibition of the Raf/MEK/ERK cascade by the MEK inhibitor U0126 (2–10  $\mu$ g/ml) did not result in reduced human APOBEC3G mRNA levels in virus-infected A549 cells (data not shown). Activation of the p38 signalling cascade by virus infection

involves the phosphorylation of p38 by the MAP kinase kinase, MKK6. To block the pathway at this level of the cascade we overexpressed a dominant negative mutant of MKK6 (MKK6Ala) that was previously shown to efficiently suppress the activation of p38 [24]. Successful transduction of the retroviral vector pEGZ-MKK6Ala was monitored by FACS-analysis of GFP (data not shown) that is expressed from a second reading frame of the mRNA of the transgene [24]. Inhibition of the p38 phosphorylation by either stable overexpression of the dominant-negative form of MKK6 (Figure 2A) or application of the p38 inhibitor SB203580 (20  $\mu$ M) (data not shown) did not affect the induced transcription of APOBEC3G. These findings argue against a prominent role of either, ERK or p38 MAPK cascade in viral APOBEC3G induction.

The IKK2/NF- $\kappa$ B module is another influenza virus-activated signalling cascade that is known to regulate a variety of genes. This includes IFN $\beta$  transcription, which is controlled by an enhanceosome, composed of the transcription factors IRF3/7, NF- $\kappa$ B, and AP-1 [22]. To assess the involvement of IKK2 and NF- $\kappa$ B in virus-induced APOBEC3G expression, we used A549 cells that were retrovirally transduced with the vector pEGZ-IKK2KD. This transduction allows for the stable expression of the dominant negative mutant of I $\kappa$ B kinase 2 (IKK2), an approach that has been successfully used previously to efficiently blunt NF- $\kappa$ B activity [25,26]. Upon infection of these mutant-expressing cells, APOBEC3G mRNA levels were reduced compared to control cells (Figure 2A) to a similar extent that was observed for the IFN $\beta$  gene (Figure 2B). The same pattern of APOBEC3G expression was also observed in infected cells pre-treated with the NF- $\kappa$ B inhibitor BAY 11-7085 (40  $\mu$ M) (Figure 2C). Thus, NF- $\kappa$ B activity appeared to be crucial for viral APOBEC3G induction.

To independently analyse whether NF- $\kappa$ B might play a role in APOBEC3G induction, we stimulated cells with TNF $\alpha$  (20 ng/ml), a very strong activator of NF- $\kappa$ B [27]. However, TNF $\alpha$  stimulation did not result in enhanced APOBEC3G gene transcription (data not shown), indicating that NF- $\kappa$ B activity alone is not sufficient to induce human APOBEC3G gene transcription.

Influenza virus infection results in type I IFN production (Figure 2B) and subsequent expression of IFN-responsive genes [28-30]. So far, it was not clear from the literature whether human APOBEC3 genes are induced by type I IFNs. While IFN-dependency was reported for the hepatoma cell lines HepG2 and Huh7 [18,31] and for macrophages [32], human APOBEC3 proteins are not inducible in H9 cells by type I and type II IFN [23]. To specifically address this issue for the lung epithelial cell line used in our study, A549 cells were incubated for different

**A**


human APOBEC3F primer

Plasmid copy number	hA3F			hA3G		
10 <sup>6</sup>	10 <sup>4</sup>	10 <sup>2</sup>	10 <sup>6</sup>	10 <sup>4</sup>	10 <sup>2</sup>	
CT-value	21.5	28.7	32.8	>40	>40	>40


human APOBEC3G primer

Plasmid copy number	hA3F			hA3G		
10 <sup>6</sup>	10 <sup>4</sup>	10 <sup>2</sup>	10 <sup>6</sup>	10 <sup>4</sup>	10 <sup>2</sup>	
CT-value	>40	>40	>40	21.5	28.2	>40


**B**




**C**



**D**



**E**



**Figure 1** (see legend on next page)

**Figure 1** (see previous page)

**Virus-induced human APOBEC3G gene transcription.** (A) Determination of the binding specificity of human APOBEC3F and human APOBEC3G primers in quantitative real time PCR (qRT-PCR). Serial dilutions of the C-terminally HA-tagged plasmids pcDNA\_huAPOBEC3F (hA3F) (described by H. Muckenfuss and colleagues) or pcDNA\_huAPOBEC3G (generously provided by Nathaniel R. Landau) were analysed using either human APOBEC3F or APOBEC3G specific primer pairs in qRT-PCR. The copy number of each plasmid and the corresponding CT-values (cycle number of the first detectable signal) are given. Low CT-values indicate high amounts of the DNA-sequence of interest. CT-values above 30 are commonly considered as non-specific signals. The qRT-PCR-program is limited to 40 cycles; due to that fact that CT-values >40 indicate undetectable amounts of DNA. (B-E) The influenza virus strain A/Puerto Rico/8/34 H1N1 (PR8) was diluted in PBS containing 0.6% sterile BSA and 1% penicillin/streptomycin and used to infect A549 cells (B and D-E) or HUVEC (C) (MOI = 5) for the time points indicated. At two-hourly intervals post infection, RNA was isolated using the RNeasy mini-kit (Qiagen), and 3 µg of total RNA were transcribed into cDNA using 0.5 µg oligo dT-primer (16 mer) and 200 U Revert Aid H<sup>-</sup> (Fermentas) according to the manufacturer's protocol. mRNA levels of IFNβ, human APOBEC3F and human APOBEC3G were assessed by qRT-PCR using primer pairs for human APOBEC3F and 3G; or for human IFNβ as follows: IFNβ\_fwd 5'-GGC CAT GAC CAA CAA GTG TCT CCT CC-3' and IFNβ\_rev 5'-GCG CTC AGT TTC GGA GGT AAC CTG T-3'. Induced transcription of mRNA was calculated as n-fold using GAPDH as reference gene. (D) Determination of the copy numbers per cell of human APOBEC3F or human APOBEC3G. (E) Infected A549 cells were lysed at the time points indicated. Endogenous expression of human APOBEC3G was determined with the hA3G specific antibody ApoC17 (NIH AIDS Research and Reference Reagent Program) in Western blots. An anti-tubulin (B5-1-2, Sigma) blot served as a loading control.


time periods with recombinant IFNβ (100 U/ml) (PBL), and the levels of human APOBEC3G and human APOBEC3F mRNAs were determined by qRT-PCR (Figure 2D).

IFNβ stimulation led to a nearly 20-fold induction of the human APOBEC3G mRNA (Figure 2D), which could also be observed at the protein level (Figure 2E); by contrast, the human APOBEC3F mRNA was not affected at all (Figure 2D). Strikingly, this pattern of human APOBEC3G versus human APOBEC3F expression exactly matched the results obtained upon virus infection (Figure 1B). This suggests that IFNβ, expressed upon virus infection in an NF-κB dependent manner, may be an indirect trigger of human APOBEC3G expression, leaving still open the question about the initial viral inducer.

IFNβ transcription in infected cells is known to be mainly induced by single-stranded or partially double-stranded RNA. Such RNA species accumulate during infection within the host cell and serve as a pathogen pattern sensed by cells [33,34]. To examine whether different RNA species serve as inducer of APOBEC3G gene expression, total RNAs isolated from influenza virus infected ("viral RNA") or uninfected cells ("cellular RNA"), or the dsRNA analogue poly (I:C), or short ssRNA bearing a 5'-triphosphate were used as stimuli to elicit a gene response. These RNAs were transfected into A549 cells, and mRNA levels of human APOBEC3G and IFNβ were determined (Figure 3A-D). While transfection of RNA from uninfected cells led to no significant gene induction, RNA from virally infected cells resulted in upregulation of both, human APOBEC3G and IFNβ transcription (Figure 3A and 3B). Stimulation using either poly (I:C) or 5'-triphosphate

RNA led to even a stronger induction of APOBEC3G (Figure 3C and 3D). In summary, our findings indicate that human APOBEC3G is induced upon viral infection as a part of the antiviral response mediated by type I IFN. This response is triggered by the recognition of different RNA species by distinct receptors such as TLR3, RIG-I and/or MDA-5. Interestingly, we did not observe any human APOBEC3F induction, neither upon viral infection nor with IFNβ stimulation (Figure 1B and 2D), albeit both promoters carry ISRE elements [35]. Thus, we hypothesized that human APOBEC3G may be selectively induced and may confer a specific antiviral activity in influenza virus infected cells.


To test this assumption we first transiently over expressed HA-tagged human APOBEC3G (Figure 4B) and assessed the efficiency of viral propagation in these cells. Surprisingly, in the presence of human APOBEC3G, progeny virus titres were slightly elevated compared to the vector control (Figure 4A, white bars). This correlated with a slightly higher expression level of the viral polymerase subunit PB1 (Figure 4B). To circumvent potential transient transfection artefacts and to enhance the number of transgene-expressing cells, we generated cell lines, stably expressing human APOBEC3G (Figure 4C and 4D). After selection of stably APOBEC3G expressing cells by antibiotic treatment, the cells were infected with different influenza A virus strains at various multiplicities of infection (MOI) (Figure 4A, grey and black bars). In contrast to the transient situation, viral propagation was not affected in these stably transfected cells, although the transgene was expressed well in MDCK cells (Figure 4C) as well as in A549 cells (Figure 4D). Thus, although influenza A virus induces human APOBEC3G transcription in an NF-κB



**Figure 2**  
**IFNβ-induced transcription of human APOBEC3G.** (A and B) A549 cells stably overexpressing the dominant negative mutants IKK2KD or MKK6Ala. These mutant kinases were cloned in the retroviral pEGZ-vector. In this vector GFP is expressed by an internal ribosomal entry site (IRES) from the same mRNA as the IKK2KD and MKK6Ala transgenes, allowing transgene expression to be monitored by FACS-analysis (data not shown). MKK6Ala and IKK2KD overexpressing cells were infected for 10 hours with the influenza A virus strain PR8 (MOI = 5). Following infection, RNA was isolated with the RNeasy mini kit (Qiagen), reverse transcribed as described above, and cDNA was subjected to qRT-PCR. (C) A549 cells were pre-treated for 30 minutes with the NF-κB specific inhibitor BAY 11-7085 (40 μM) before infection with PR8 (MOI = 5) for 10 hours. RNA was subjected to qRT-PCR. The mRNA levels of human APOBEC3G (A and C) or IFNβ (B) were assessed by qRT-PCR. (D) A549 cells were stimulated with IFNβ (100 U/ml) (Invitrogen) for the time points indicated. The mRNA levels of human APOBEC3F and human APOBEC3G were determined by means of qRT-PCR. Induction of gene transcription was calculated as n-fold of untreated cells, which was arbitrarily set as 1, as described by Livak and Schmittgen. (E) A549 cells were stimulated as in (D), and cell lysates were subjected to Western blots using the hA3G specific antibody ApoC17 (NIH)


and IFNβ dependent manner, the forced expression of human APOBEC3G did not result in any antiviral effect on this virus. This is different from the situation with HIV-1. APOBEC3G shows antiviral activity against HIV-1 and other retroviruses [8,2]. However, HIV-1 does not induce APOBEC3G transcription in cell culture [2,3]. In support of a specific rather than broad antiviral activity of

APOBEC3G, Kremer et al. [36] had reported that overexpressed human APOBEC3G also has no antiviral effect against vaccinia virus (VACV). In summary, we conclude that human APOBEC3G is induced by influenza A viral RNA, via an NF-κB dependent mechanism as part of the antiviral IFN response program but does not exhibit an antiviral effect against influenza A virus.



**Figure 3**

**Induction of human APOBEC3G mRNA by different RNA species.** (A and B) A549 cells ( $1.5 \times 10^6$ /6 cm dish) were transfected with indicated amounts of total RNA from virally infected ("viral RNA") or uninfected ("cellular RNA") A549 cells. RNA from uninfected or virally infected cells was generated by isolation of total RNA from cells either infected with PR8 (MOI = 5) or from uninfected cells using the Qiagen RNeasy kit according to the manufacturer's instructions. For stimulation, these RNAs were transfected for 10 hours using Lipofectamine 2000 (L2000) (Invitrogen) according to the manufacturer's protocol. (C) A549 cells were transfected with either different amounts of poly (I:C) (Amersham Biosciences) or with 5'-triphosphate RNA (D). 5'-triphosphate RNA was generated by reverse transcription of a short PCR product using the MEGAscript kit (Ambion) according to the manufacturer's instructions. mRNA levels of IFNβ (B) or human APOBEC3G (A, C and D) were determined by qRT-PCR as described. Levels of gene induction were calculated as n-fold of the background of untreated cells, which was arbitrarily set as 1.



**Figure 4** (see legend on next page)

**Figure 4** (see previous page)

**Influence of the human APOBEC3G protein on viral replication.** (A) Transiently (white bars) or stably human APOBEC3G transfected (light and dark grey bars) MDCK cells were infected with avian influenza virus A/FPV/Bratislava/79 (H7N7) (FPV) (MOI = 0.05) for 9 hours or A/Puerto Rico/8/34 H1N1 (PR8) (MOI = 0.1) virus for 16 hours. Both virus strains were originally taken from the collection of the Institute of Virology, University of Giessen, Germany. Stably transfected A549 cells (black bars) were infected with PR8 for 16 hours (MOI = 0.01). Supernatants were taken, and virus titres were determined by means of plaque assay. (B and C) MDCK cells or (D) A549 cells were transfected with 3 µg DNA/6 well dish pcDNA-APOBEC3G or pcDNA3.1 empty vector using L2000 (Invitrogen) according to manufacturer's instructions. To generate a bulk amount of stable expressing cells, MDCK cells (C) or A549 cells (D) were treated with G418 300 µg/ml for selection of APOBEC3G expression for four weeks. Thereafter, cells were infected with FPV at MOI = 0.05 (B) or at MOI = 0.1 for 9 hours (C) or with PR8 at MOI = 0.001 for 16 hours (D). Expression of HA-tagged human-APOBEC3G was detected by anti-HA 3F10 (Roche) antibody. To control equivalent protein loading, ERK2 or JNK were detected by anti-ERK2 (Santa Cruz) or anti-JNK antibody (Santa Cruz). Viral replication was monitored by detection of the viral polymerase protein using an anti-PB1 antibody (Santa Cruz).

**Competing interests**

The authors declare that they have no competing interests.

**Authors' contributions**

EKP, MS, CE and HH have performed experimental work, contributed data and gave conceptual input in the study design. EF and CM have provided important material and have been involved in drafting the manuscript and revising it critically for important intellectual content. SL has designed and has guided the study, interpreted the data and wrote the manuscript.

**Acknowledgements**

The following reagent was obtained through the NIH AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH: anti-ApoC17 from Dr. Klaus Strebler. This work was supported by several grants from the Deutsche Forschungsgemeinschaft (DFG) (Lu477-11/2, SFB293 A17, Graduate School GRK1409), the Interdisciplinary Clinical Research Centre (IZKF) of the University of Münster, the *FluResearchNet* funded by the German Ministry of Education and Research (BMBF), and the EC funded STREP EUROFLU.

**References**

- Ulunga NK, Sarr AD, Thakore-Meloni S, Sankale JL, Eisen G, Kanki PJ: **Relationship between human immunodeficiency type 1 infection and expression of human APOBEC3G and APOBEC3F.** *J Infect Dis* 2008, **198**:486-492.
- Stopak K, de Noronha C, Yonemoto W, Greene WC: **HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability.** *Mol Cell* 2003, **12**:591-601.
- Mehle A, Strack B, Ancuta P, Zhang C, McPike M, Gabuzda D: **Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway.** *J Biol Chem* 2004, **279**:7792-7798.
- Bishop KN, Holmes RK, Sheehy AM, Davidson NO, Cho SJ, Malim MH: **Cytidine deamination of retroviral DNA by diverse APOBEC proteins.** *Curr Biol* 2004, **14**:1392-1396.
- Wiegand HL, Doehle BP, Bogerd HP, Cullen BR: **A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins.** *EMBO J* 2004, **23**:2451-2458.
- Turelli P, Mangeat B, Jost S, Vianin S, Trono D: **Inhibition of hepatitis B virus replication by APOBEC3G.** *Science* 2004, **303**:1829.
- Chen H, Lilley CE, Yu Q, Lee DV, Chou J, Narvaiza I, Landau NR, Weitzman MD: **APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons.** *Curr Biol* 2006, **16**:480-485.
- Sheehy AM, Gaddis NC, Choi JD, Malim MH: **Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein.** *Nature* 2002, **418**:646-650.
- Harris RS, Bishop KN, Sheehy AM, Craig HM, Petersen-Mahrt SK, Watt IN, Neuberger MS, Malim MH: **DNA deamination mediates innate immunity to retroviral infection.** *Cell* 2003, **113**:803-809.
- Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D: **Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.** *Nature* 2003, **424**:99-103.
- Goila-Gaur R, Strebler K: **HIV-1 Vif, APOBEC, and intrinsic immunity.** *Retrovirology* 2008, **5**:51.
- Pillai SK, Wong JK, Barbour JD: **Turning up the volume on mutational pressure: is more of a good thing always better? (A case study of HIV-1 Vif and APOBEC3).** *Retrovirology* 2008, **5**:26.
- Bishop KN, Holmes RK, Sheehy AM, Malim MH: **APOBEC-mediated editing of viral RNA.** *Science* 2004, **305**:645.
- Newman EN, Holmes RK, Craig HM, Klein KC, Lingappa JR, Malim MH, Sheehy AM: **Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity.** *Curr Biol* 2005, **15**:166-170.
- Shindo K, Takaori-Kondo A, Kobayashi M, Abudu A, Fukunaga K, Uchiyama T: **The enzymatic activity of CEM15/Apobec-3G is essential for the regulation of the infectivity of HIV-1 virion but not a sole determinant of its antiviral activity.** *J Biol Chem* 2003, **278**:44412-44416.
- Cho SJ, Drechsler H, Burke RC, Arens MQ, Powderly W, Davidson NO: **APOBEC3F and APOBEC3G mRNA levels do not correlate with human immunodeficiency virus type 1 plasma viremia or CD4+ T-cell count.** *J Virol* 2006, **80**:2069-2072.
- Livak KJ, Schmittgen TD: **Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method.** *Methods* 2001, **25**:402-408.
- Tanaka Y, Marusawa H, Seno H, Matsumoto Y, Ueda Y, Kodama Y, Endo Y, Yamauchi J, Matsumoto T, Takaori-Kondo A, Ikai I, Chiba T: **Anti-viral protein APOBEC3G is induced by interferon-alpha stimulation in human hepatocytes.** *Biochem Biophys Res Commun* 2006, **341**:314-319.
- Muckenfuss H, Hamdorf M, Held U, Perkovic M, Löwer J, Cichutek K, Flory E, Schumann GG, Münk C: **APOBEC3 proteins inhibit human LINE-1 retrotransposition.** *J Biol Chem* 2006, **281**:22161-22172.
- Mariani R, Chen D, Schräfelbauer B, Navarro F, König R, Bollmann B, Münk C, Nymark-McMahon H, Landau NR: **Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif.** *Cell* 2003, **114**:21-31.
- Ludwig S: **Exploited defense: how influenza viruses take advantage of antiviral signaling responses.** *Future Virol* 2007, **2**:91-100.
- Ludwig S, Pleschka S, Planz O, Wolff T: **Ring the alarm bells: signalling and apoptosis in influenza virus infected cells.** *Cell Microbiol* 2006, **8**:375-386.



23. Rose KM, Marin M, Kozak SL, Kabat D: **Transcriptional regulation of APOBEC3G, a cytidine deaminase that hypermutates human immunodeficiency virus.** *J Biol Chem* 2004, **279**:41744-41749.
24. Ludwig S, Hoffmeyer A, Moebeler M, Kilian K, Häfner H, Neufeld B, Han J, Rapp UR: **The stress inducer arsenite activates mitogen-activated protein kinase extracellular signal-regulated kinases 1 and 2 via a MAPK kinase 6/p38-dependent pathway.** *J Biol Chem* 1998, **273**:1917-1922.
25. Wurzer WJ, Ehrhardt C, Pleschka S, Berberich-Siebelt F, Wolff T, Walczak H, Planz O, Ludwig S: **NF-kappaB-dependent induction of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and Fas/FasL is crucial for efficient influenza virus propagation.** *J Biol Chem* 2004, **279**:30931-30937.
26. Viemann D, Goebeler M, Schmid S, Klimmek K, Sorg C, Ludwig S, Roth J: **Transcriptional profiling of IKK2/NF-kappa B- and p38 MAP kinase-dependent gene expression in TNF-alpha-stimulated primary human endothelial cells.** *Blood* 2004, **103**:3365-3373.
27. Cao Z, Tanaka M, Regnier C, Rothe M, Yamit-hezi A, Woronicz JD, Fuentes ME, Durnin MH, Dalrymple SA, Goeddel DV: **NF-kappa B activation by tumor necrosis factor and interleukin-1.** *Cold Spring Harb Symp Quant Biol* 1999, **64**:473-483.
28. Geiss G, Jin G, Guo J, Bumgarner R, Katze MG, Sen GC: **A comprehensive view of regulation of gene expression by double-stranded RNA-mediated cell signaling.** *J Biol Chem* 2001, **276**:30178-30182.
29. Geiss GK, An MC, Bumgarner RE, Hammersmark E, Cunningham D, Katze MG: **Global impact of influenza virus on cellular pathways is mediated by both replication-dependent and -independent events.** *J Virol* 2001, **75**:4321-4331.
30. Geiss GK, Salvatore M, Tumphey TM, Carter VS, Wang X, Basler CF, Taubenberger JK, Bumgarner RE, Palese P, Katze MG, Garcia-Sastre A: **Cellular transcriptional profiling in influenza A virus-infected lung epithelial cells: the role of the nonstructural NS1 protein in the evasion of the host innate defense and its potential contribution to pandemic influenza.** *Proc Natl Acad Sci USA* 2002, **99**:10736-10741.
31. Bonvin M, Achermann F, Greeve I, Stroka D, Keogh A, Inderbitzin D, Candinas D, Sommer P, Wain-Hobson S, Vartanian JP, Greeve J: **Interferon-inducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication.** *Hepatology* 2006, **43**:1364-1374.
32. Peng G, Lei KJ, Jin W, Greenwell-Wild T, Wahl SM: **Induction of APOBEC3 family proteins, a defensive maneuver underlying interferon-induced anti-HIV-1 activity.** *J Exp Med* 2006, **203**:41-46.
33. Hornung V, Ellegast J, Kim S, Brzozka K, Jung A, Kato H, Poeck H, Akira S, Conzelmann KK, Schlee M, Endres S, Hartmann G: **5'-Triphosphate RNA is the ligand for RIG-I.** *Science* 2006, **314**:994-997.
34. Pichlmair A, Schulz O, Tan CP, Naslund TI, Liljestrom P, Weber F, Reis e Sousa C: **RIG-I-mediated antiviral responses to single-stranded RNA bearing 5'-phosphates.** *Science* 2006, **314**:997-1001.
35. Chen K, Huang J, Zhang C, Huang S, Nunnari G, Wang FX, Tong X, Gao L, Nikisher K, Zhang H: **Alpha interferon potently enhances the anti-human immunodeficiency virus type 1 activity of APOBEC3G in resting primary CD4 T cells.** *J Virol* 2006, **80**:7645-7657.
36. Kremer M, Suezzer Y, Martinez-Fernandez Y, Munk C, Sutter G, Schnierle BS: **Vaccinia virus replication is not affected by APOBEC3 family members.** *Virol J* 2006, **3**:86.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:  
[http://www.biomedcentral.com/info/publishing\\_adv.asp](http://www.biomedcentral.com/info/publishing_adv.asp)

